Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PSPersonalis, Inc. logo

Personalis, Inc. (PSNL)

NASDAQ Global Market · Currency in USD
$15.85 ▲ +0.03 (+0.19%)
At close: Oct 23, 4:00 PM ET. Market closed.
$15.85 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$15.82
Open
$15.76
Day's Range
$15.74 – $15.89
52 Week Range
$4.96 – $18.89
Volume
1,115,864
Avg. Volume
3,545,114
Market Cap
$1.69B
Beta (5Y Monthly)
2.32
PE Ratio (TTM)
--
EPS (TTM)
-$1.02
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$14.95

Profile: Personalis, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
260
CEO
Christopher Hall

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.26 · Revenue est. $21.54M
DateEst.Actual
Aug 4, 2026-$0.26-$0.30Miss
May 7, 2026-$0.23-$0.29Miss
Feb 26, 2026-$0.31-$0.26Beat
Nov 4, 2025-$0.28-$0.24Beat
Aug 5, 2025-$0.25-$0.23Beat
May 6, 2025-$0.23-$0.18Beat

Analyst view

Consensus price target
$14.95 ▼ -5.7%
Range $9.00 – $17.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on PSNL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.